Why Is Rigetti Stock Going Up?
Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…
Buy
68
COR Quote, Financials, Valuation and Earnings
Last price:
$290.21
Seasonality move
:
5.31%
Day range:
$285.48 - $290.54
52-week range:
$214.77 - $309.35
Dividend yield:
0.74%
P/E ratio:
33.67x
P/S ratio:
0.18x
P/B ratio:
55.51x
Volume:
1.4M
Avg. volume:
2.1M
1-year change:
30.82%
Market cap:
$56.2B
Revenue:
$294B
EPS (TTM):
$8.62
Analysts' Opinion
-
Consensus RatingCencora has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $317.09, Cencora has an estimated upside of 9.26% from its current price of $290.22.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $256.33 representing 11.68% downside risk from its current price of $290.22.
Fair Value
-
According to the consensus of 15 analysts, Cencora has 9.26% upside to fair value with a price target of $317.09 per share.
COR vs. S&P 500
-
Over the past 5 trading days, Cencora has underperformed the S&P 500 by -2.4% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cencora does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cencora has grown year-over-year revenues for 51 quarters straight. In the most recent quarter Cencora reported revenues of $75.5B.
Earnings Growth
-
Cencora has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cencora reported earnings per share of $3.68.
Enterprise value:
62.3B
EV / Invested capital:
6.89x
Price / LTM sales:
0.18x
EV / EBIT:
23.86x
EV / Revenue:
0.20x
PEG ratio (5yr expected):
2.14x
EV / Free cash flow:
17.42x
Price / Operating cash flow:
16.00x
Enterprise value / EBITDA:
16.76x
Gross Profit (TTM):
$10.5B
Return On Assets:
2.51%
Net Income Margin (TTM):
0.55%
Return On Equity:
183.42%
Return On Invested Capital:
24.2%
Operating Margin:
1.59%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $247.5B | $276.5B | $310.2B | $68.4B | $75.5B | |
| Gross Profit | $8.4B | $9.5B | $10.5B | $2.5B | $3.1B | |
| Operating Income | $2.6B | $2.9B | $3.5B | $877.5M | $1.2B | |
| EBITDA | $3B | $3.7B | $3.7B | $823.6M | $1.3B | |
| Diluted EPS | $7.78 | $9.14 | $8.62 | $2.09 | $3.68 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $35.5B | $39.4B | $40B | $44.2B | $46.5B | |
| Total Assets | $47B | $57.3B | $58.8B | $63.9B | $71.2B | |
| Current Liabilities | $33B | $42.8B | $45.1B | $49.8B | $53.3B | |
| Total Liabilities | $47.1B | $56.4B | $58.3B | $62.6B | $70B | |
| Total Equity | -$102.8M | $906.1M | $511.1M | $1.2B | $1.2B | |
| Total Debt | $6.2B | $6.5B | $4.9B | $5.2B | $7.9B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.9B | $2.6B | $4.1B | -$878.4M | $3.4B | |
| Cash From Investing | -$1.6B | -$1.2B | -$4.8B | -$166.5M | -$4.1B | |
| Cash From Financing | -$3.1B | -$717.4M | $614.9M | $323.2M | -$491.7M | |
| Free Cash Flow | $2.4B | $2.1B | $3.6B | -$991.2M | $3.2B | |
COR
Sector
Market Cap
$56.2B
$34.2M
Price % of 52-Week High
93.82%
43.73%
Dividend Yield
0.74%
0%
Shareholder Yield
2.39%
-0.66%
1-Year Price Total Return
30.82%
-41.71%
Beta (5-Year)
0.604
0.657
Dividend yield:
0.74%
Annualized payout:
$2.04
Payout ratio:
25.13%
Growth streak:
19 years
Technicals
8-day SMA
Buy
Level
$285.51
200-day SMA
Buy
Level
$248.30
Bollinger Bands (100)
Buy
Level
240.04 - 280.94
Chaikin Money Flow
Buy
Level
401.5M
20-day SMA
Buy
Level
$287.02
Relative Strength Index (RSI14)
Buy
Level
56.25
ADX Line
Buy
Level
20.97
Williams %R
Neutral
Level
-49.8827
50-day SMA
Buy
Level
$277.95
MACD (12, 26)
Buy
Level
1.80
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
357.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.8843)
Sell
CA Score
(Annual)
Level (-0.7789)
Buy
Beneish M-Score
(Annual)
Level (-2.5284)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (2.064)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Stock Forecast FAQ
In the current month, COR has received 9 Buy ratings 6 Hold ratings, and 0 Sell ratings. The COR average analyst price target in the past 3 months is $317.09.
-
Where Will Cencora Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cencora share price will rise to $317.09 per share over the next 12 months.
-
What Do Analysts Say About Cencora?
Analysts are divided on their view about Cencora share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cencora is a Sell and believe this share price will drop from its current level to $256.33.
-
What Is Cencora's Price Target?
The price target for Cencora over the next 1-year time period is forecast to be $317.09 according to 15 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is COR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cencora is a Buy. 9 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of COR?
You can purchase shares of Cencora via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cencora shares.
-
What Is The Cencora Share Price Today?
Cencora was last trading at $290.21 per share. This represents the most recent stock quote for Cencora. Yesterday, Cencora closed at $290.22 per share.
-
How To Buy Cencora Stock Online?
In order to purchase Cencora stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
How to Change Your Stock Portfolio During a Bear Market
The standard definition of a bear market is that one…
Why Is Newegg Commerce Up So Much?
Consumer electronics eCommerce store Newegg (NASDAQ:NEGG) has staged a dramatic…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 38x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
81
SMLR alert for May 19
Semler Scientific [SMLR] is up 4.97% over the past day.
Sell
25
GLOB alert for May 19
Globant SA [GLOB] is up 1.65% over the past day.
Buy
94
HIMS alert for May 19
Hims & Hers Health [HIMS] is down 4.58% over the past day.
